Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade.

Möller M, Turzer S, Schütte W, Seliger B, Riemann D.

J Immunother. 2019 Oct 4. doi: 10.1097/CJI.0000000000000297. [Epub ahead of print]

PMID:
31592989
2.

The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.

Seliger B.

Front Immunol. 2019 Sep 6;10:2043. doi: 10.3389/fimmu.2019.02043. eCollection 2019. Review.

3.

Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism.

Kappler M, Pabst U, Weinholdt C, Taubert H, Rot S, Kaune T, Kotrba J, Porsch M, Güttler A, Bache M, Krohn K, Bull F, Riemann A, Wickenhauser C, Seliger B, Schubert J, Al-Nawas B, Thews O, Grosse I, Vordermark D, Eckert AW.

Int J Mol Sci. 2019 Sep 24;20(19). pii: E4742. doi: 10.3390/ijms20194742.

5.

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.

Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B.

Cancer Immunol Immunother. 2019 Aug 3. doi: 10.1007/s00262-019-02373-1. [Epub ahead of print] Review.

PMID:
31375885
6.

PIR-B expressing CD8+ T cells exhibit features of Tc1 and Tc17 in SKG mice.

Rothe K, Quandt D, Köhler G, Jasinski-Bergner S, Seliger B, Pierer M, Wagner U.

Rheumatology (Oxford). 2019 Jun 29. pii: kez256. doi: 10.1093/rheumatology/kez256. [Epub ahead of print]

PMID:
31257448
7.

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.

Seliger B.

Front Immunol. 2019 May 22;10:999. doi: 10.3389/fimmu.2019.00999. eCollection 2019. Review.

8.

Monoallelic expression in melanoma.

Silcock L, Almabrazi H, Mokrab Y, Jithesh P, Al-Hashmi M, James N, Mathew R, Mattei V, Bedognetti D, Lessi F, Temanni R, Seliger B, Al-Ali R, Marincola FM, Wang E, Tomei S.

J Transl Med. 2019 Apr 5;17(1):112. doi: 10.1186/s12967-019-1863-x.

9.

"Tumor Immunology Meets Oncology (TIMO) XIV", May 24-26th 2018, Halle/Saale, Germany.

Steven A, Seliger B.

Cancer Immunol Immunother. 2019 Apr 4. doi: 10.1007/s00262-019-02329-5. [Epub ahead of print] No abstract available.

PMID:
30949754
10.

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma.

Tretbar S, Krausbeck P, Müller A, Friedrich M, Vaxevanis C, Bukur J, Jasinski-Bergner S, Seliger B.

Oncotarget. 2019 Feb 19;10(15):1507-1524. doi: 10.18632/oncotarget.26682. eCollection 2019 Feb 19.

11.

Identification of Immune Modulatory miRNAs by miRNA Enrichment via RNA Affinity Purification.

Tretbar US, Friedrich M, Lazaridou MF, Seliger B.

Methods Mol Biol. 2019;1913:81-101. doi: 10.1007/978-1-4939-8979-9_6.

PMID:
30666600
12.

Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells.

Wickenhauser C, Bethmann D, Feng Z, Jensen SM, Ballesteros-Merino C, Massa C, Steven A, Bauer M, Kaatzsch P, Pazaitis N, Toma G, Bifulco CB, Fox BA, Seliger B.

Methods Mol Biol. 2019;1913:13-31. doi: 10.1007/978-1-4939-8979-9_2.

PMID:
30666596
13.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C.

Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018.

PMID:
30524909
14.

Blood immune cell biomarkers in lung cancer.

Riemann D, Cwikowski M, Turzer S, Giese T, Grallert M, Schütte W, Seliger B.

Clin Exp Immunol. 2019 Feb;195(2):179-189. doi: 10.1111/cei.13219. Epub 2018 Nov 9.

PMID:
30246868
15.

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.

Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N.

Urol Oncol. 2018 Nov;36(11):502.e15-502.e24. doi: 10.1016/j.urolonc.2018.07.013. Epub 2018 Aug 28.

PMID:
30170981
16.

Kallikrein-related peptidases are activators of the CC chemokine CCL14.

Grünberg M, Quandt D, Cynis H, Demuth HU, Kindermann A, Magdolen V, Forssmann WG, Seliger B, Mägert HJ.

Eur J Immunol. 2018 Sep;48(9):1592-1594. doi: 10.1002/eji.201747452. Epub 2018 Aug 22.

17.

Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome.

Subbarayan K, Seliger B.

Curr Cancer Drug Targets. 2019;19(3):210-221. doi: 10.2174/1568009618666180706165845.

PMID:
29984655
18.

The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer.

Steven A, Seliger B.

Breast Care (Basel). 2018 Mar;13(1):16-21. doi: 10.1159/000486585. Epub 2018 Feb 2. Review.

19.

Immunotherapy of Breast Cancer.

Seliger B.

Breast Care (Basel). 2018 Mar;13(1):5-6. doi: 10.1159/000486927. Epub 2018 Feb 13. No abstract available.

20.

Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Subbarayan K, Leisz S, Wickenhauser C, Bethmann D, Massa C, Steven A, Seliger B.

Oncoimmunology. 2018 Jan 16;7(4):e1373233. doi: 10.1080/2162402X.2017.1373233. eCollection 2018.

21.

Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma.

Eckert AW, Wickenhauser C, Salins PC, Kappler M, Bukur J, Seliger B.

J Transl Med. 2018 Feb 28;16(1):40. doi: 10.1186/s12967-018-1407-9.

22.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. No abstract available.

23.

Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation.

Lennicke C, Rahn J, Wickenhauser C, Lichtenfels R, Müller AS, Wessjohann LA, Kipp AP, Seliger B.

Oncotarget. 2017 Nov 23;9(1):539-552. doi: 10.18632/oncotarget.22640. eCollection 2018 Jan 2.

24.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. Erratum in: Immunity. 2018 Feb 20;48(2):396-398.

25.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

26.

Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue.

Polovic M, Dittmar S, Hennemeier I, Humpf HU, Seliger B, Fornara P, Theil G, Azinovic P, Nolze A, Köhn M, Schwerdt G, Gekle M.

Cell Mol Life Sci. 2018 Jun;75(12):2241-2256. doi: 10.1007/s00018-017-2731-6. Epub 2017 Dec 27.

PMID:
29282485
27.

The tumor microenvironment: Thousand obstacles for effector T cells.

Massa C, Seliger B.

Cell Immunol. 2019 Sep;343:103730. doi: 10.1016/j.cellimm.2017.12.004. Epub 2017 Dec 8.

PMID:
29249298
28.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14.

29.

Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin.

Jasinski-Bergner S, Büttner M, Quandt D, Seliger B, Kielstein H.

Obes Facts. 2017;10(6):569-583. doi: 10.1159/000481732. Epub 2017 Dec 6.

30.

The role of the miR-148/-152 family in physiology and disease.

Friedrich M, Pracht K, Mashreghi MF, Jäck HM, Radbruch A, Seliger B.

Eur J Immunol. 2017 Dec;47(12):2026-2038. doi: 10.1002/eji.201747132. Epub 2017 Sep 29. Review.

31.

Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors.

Seliger B.

Cytokine Growth Factor Rev. 2017 Aug;36:49-56. doi: 10.1016/j.cytogfr.2017.07.001. Epub 2017 Jul 13. Review.

PMID:
28739030
32.

Multiparametric immune profiling in HPV- oral squamous cell cancer.

Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA.

JCI Insight. 2017 Jul 20;2(14). pii: 93652. doi: 10.1172/jci.insight.93652. eCollection 2017 Jul 20.

33.

"Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.

Seliger B.

Cancer Immunol Immunother. 2017 Nov;66(11):1497-1503. doi: 10.1007/s00262-017-2037-4. Epub 2017 Jul 10. No abstract available.

PMID:
28695228
34.

Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.

Lennicke C, Rahn J, Bukur J, Hochgräfe F, Wessjohann LA, Lichtenfels R, Seliger B.

Oncoimmunology. 2016 Dec 21;6(6):e1259049. doi: 10.1080/2162402X.2016.1259049. eCollection 2017.

35.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

36.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

37.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
38.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
39.

Immunotherapy for metastatic renal cell carcinoma.

Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B.

Cochrane Database Syst Rev. 2017 May 15;5:CD011673. doi: 10.1002/14651858.CD011673.pub2. Review.

40.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.

Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Review.

41.

High constitutive B7-H3 expression on human keratinocytes supports T cell immunity.

Quandt D, Fiedler E, Müller A, Marsch WC, Seliger B.

J Dermatol Sci. 2017 Jul;87(1):82-85. doi: 10.1016/j.jdermsci.2017.02.287. Epub 2017 Apr 11. No abstract available.

PMID:
28465042
42.

Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds.

Rahn J, Lennicke C, Kipp AP, Müller AS, Wessjohann LA, Lichtenfels R, Seliger B.

Proteomics. 2017 Jun;17(11). doi: 10.1002/pmic.201600486.

PMID:
28409884
43.

Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.

Eichmüller SB, Osen W, Mandelboim O, Seliger B.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx034. Review.

PMID:
28383653
44.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

45.

HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Seliger B, Kloor M, Ferrone S.

Oncoimmunology. 2017 Feb 6;6(2):e1171447. doi: 10.1080/2162402X.2016.1171447. eCollection 2017. Review.

46.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

47.

Methionine and seleno-methionine type peptide and peptoid building blocks synthesized by five-component five-center reactions.

Kaluđerović GN, Abbas M, Kautz HC, Wadaan MA, Lennicke C, Seliger B, Wessjohann LA.

Chem Commun (Camb). 2017 Mar 28;53(26):3777-3780. doi: 10.1039/c7cc00399d.

PMID:
28304024
48.

Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients.

Massa C, Robins H, Desmarais C, Riemann D, Fahldieck C, Fornara P, Seliger B.

Oncotarget. 2017 Mar 28;8(13):21212-21228. doi: 10.18632/oncotarget.15064.

49.

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion.

Juengel E, Krueger G, Rutz J, Nelson K, Werner I, Relja B, Seliger B, Fisslthaler B, Fleming I, Tsaur I, Haferkamp A, Blaheta RA.

Oncotarget. 2017 Jan 3;8(1):1953-1954. doi: 10.18632/oncotarget.14438. No abstract available.

50.

Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.

Seliger B.

HLA. 2016 Nov;88(5):213-220. doi: 10.1111/tan.12898. Epub 2016 Sep 22. Review.

PMID:
27659281

Supplemental Content

Loading ...
Support Center